{"id":"NCT01272908","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)","officialTitle":"Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07-18","primaryCompletion":"2009-03-12","completion":"2009-03-12","firstPosted":"2011-01-10","resultsPosted":"2014-08-05","lastUpdate":"2017-08-15"},"enrollment":120,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"rituximab","otherNames":[]}],"arms":[{"label":"Single arm","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary","timeFrame":"Days 1, 2, 15, and 16 and Week 48 of Initial treatment period","effectByArm":[{"arm":"Initial Treatment Period: Rituximab + MTX","deltaMin":85,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":41,"countries":["Canada","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":120},"commonTop":["Nausea","Rheumatoid arthritis","Nasopharyngitis","Headache","Cough"]}}